Indications for: BLUDIGO
As a visualization aid in the cystoscopic assessment of the integrity of the ureters following urological and gynecological open, robotic, or endoscopic surgical procedures.
Give 5mL by IV inj over 1min. Within 4–9mins after IV inj, blue color is detectable at the ureteral orifices.
Risk of severe or life-threatening cardiovascular reactions within 60mins after inj (eg, cardiac arrest, arrhythmia, asystole, 2nd degree AV block, hypotension, elevated BP, bradycardia, tachycardia); interrupt administration if reactions occur. Hypertension. Heart rate or conduction disorders. Closely monitor BP and cardiac rhythm during and following inj. Monitor for anaphylactic reactions. Have emergency equipment and trained personnel readily available. May transiently interfere with pulse oximetric methods. Potential for artifactual reduction in SpO2 in anesthetized patients. Renal impairment (eGFR <30mL/min): not recommended. Pregnancy. Nursing mothers.
Increased risk for elevated blood pressure, hypotension, bradycardia with concomitant drugs that can cause bradycardia.
Constipation, nausea, vomiting, abdominal pain, pyrexia, increased ALT, dysuria; hypersensitivity reactions.
Generic Drug Availability:
Single-dose ampules (5mL)—5